Editas shares rose 16% after reporting a narrower-than-expected Q4 loss and beating revenue estimates, and announcing progress to advance EDIT-401 toward a first-in-human study in 2026. The earnings beat and clearer path for the gene-editing candidate materially derisk the program and likely drove the strong stock move.
Editas shares rose 16% after reporting a narrower-than-expected Q4 loss and beating revenue estimates, and announcing progress to advance EDIT-401 toward a first-in-human study in 2026. The earnings beat and clearer path for the gene-editing candidate materially derisk the program and likely drove the strong stock move.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
